Volume 27, Number 5—May 2021
Synopsis
Clinical Laboratory Perspective on Streptococcus halichoeri, an Unusual Nonhemolytic, Lancefield Group B Streptococcus Causing Human Infections
Table 2
Antimicrobial susceptibility profiles for 22 human clinical isolates of Streptococcus halichoeri, United States*
Antimicrobial agent | MIC values, µg/mL |
|||
---|---|---|---|---|
% Susceptible | Range | MIC50 | MIC90 | |
CRO | 100 | ≤0.06–0.25 | 0.12 | 0.25 |
CLI | 77.3 | ≤0.03 to ≥4 | 0.03 | ≥4 |
DAP | 100 | ≤0.12–0.5 | 0.25 | 0.25 |
DOX† | NA‡ | ≤0.25–16 | 0.25 | 0.5 |
ERY | 72.7 | ≤0.12 to ≥8 | 0.12 | 2 |
LVX | 100 | ≤0.25–2 | 1 | 1 |
LZD | 100 | 0.5–1 | 1 | 1 |
MEM | 100 | ≤0.06–0.25 | 0.06 | 0.06 |
PEN | 100 | ≤0.03–0.06 | 0.03 | 0.03 |
Q/D‡ | 94.7 | ≤0.25 to ≥4 | 0.25 | 0.25 |
VAN | 100 | ≤0.5–1 | 0.5 | 0.5 |
*CLI, clindamycin; CRO, ceftriaxone; DAP, daptomycin; DOX, doxycycline; ERY, erythromycin; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIC50, MIC value at which ≥50% of the isolates in a test population are inhibited; MIC90, MIC value at which ≥90% of the isolates in a test population are inhibited; NA, not available; PEN, penicillin; Q/D, quinupristin/dalfopristin; VAN, vancomycin. †Clinical and Laboratory Standards Institute interpretive breakpoints for doxycycline were not available for viridans group Streptococcus spp. If breakpoints for S. pneumoniae were applied, 82% would be susceptible (5). ‡n = 19 isolates.
1These authors contributed equally to this article.